Progression of EGFR-Mutant Lung Adenocarcinoma is Driven By Alveolar Macrophages

No abstract is available for this paper.

• Publication year

  2016

• Venue

  Clinical Cancer Research

• Publication date

  2016-08-05

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1158/1078-0432.CCR-15-2597PMID 27496865
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Non-Small Cell Lung Cancer

  2020cited by this paper
• Non-small Cell Lung Cancer

  2016influential reference
• Robust enumeration of cell subsets from tissue expression profiles

  2015cited by this paper
• M2-polarized macrophages contribute to the decreased sensitivity of EGFR-TKIs treatment in patients with advanced lung adenocarcinoma

  2014cited by this paper
• The cellular and molecular origin of tumor-associated macrophages

  2014cited by this paper
• EGFR signaling and autophagy dependence for growth, survival, and therapy resistance

  2014influential reference
• KIT oncogene inhibition drives intratumoral macrophage M2 polarization

  2013cited by this paper
• Role of macrophage targeting in the antitumor activity of trabectedin.

  2013cited by this paper
• Nonsmall cell lung cancer

  2013cited by this paper
• Epidermal growth factor receptor tyrosine kinase inhibitor-resistant disease.

  2013cited by this paper
• Neutralizing Tumor-Promoting Chronic Inflammation: A Magic Bullet?

  2013cited by this paper
• Cetuximab response of lung cancer-derived EGF receptor mutants is associated with asymmetric dimerization.

  2013cited by this paper
• Tissue-resident macrophages self-maintain locally throughout adult life with minimal contribution from circulating monocytes.

  2013cited by this paper
• Lung Collagens Perpetuate Pulmonary Fibrosis via CD204 and M2 Macrophage Activation

  2013cited by this paper
• A Phase I Study of an Agonist CD40 Monoclonal Antibody (CP-870,893) in Combination with Gemcitabine in Patients with Advanced Pancreatic Ductal Adenocarcinoma

  2013cited by this paper
• Anti‐tumour strategies aiming to target tumour‐associated macrophages

  2013cited by this paper
• Identification of genes upregulated in ALK-positive and EGFR/KRAS/ALK-negative lung adenocarcinomas.

  2012cited by this paper
• Therapeutic applications of macrophage colony-stimulating factor-1 (CSF-1) and antagonists of CSF-1 receptor (CSF-1R) signaling.

  2012cited by this paper
• Differential macrophage programming in the tumor microenvironment.

  2012cited by this paper
• A CXCL1 paracrine network links cancer chemoresistance and metastasis.

  2012cited by this paper
• In Vitro Generation of Monocyte-Derived Macrophages under Serum-Free Conditions Improves Their Tumor Promoting Functions

  2012cited by this paper
• Non-small cell lung cancer.

  2012cited by this paper
• A Critical Role for Macrophages in Promotion of Urethane-Induced Lung Carcinogenesis

  2011cited by this paper
• Non-small-cell lung cancer.

  2011cited by this paper
• CD40 Agonists Alter Tumor Stroma and Show Efficacy Against Pancreatic Carcinoma in Mice and Humans

  2011cited by this paper
• Imatinib potentiates anti-tumor T cell responses in gastrointestinal stromal tumor through the inhibition of Ido

  2011cited by this paper
• Prognostic gene expression signature associated with two molecularly distinct subtypes of colorectal cancer

  2011cited by this paper
• Macrophage diversity enhances tumor progression and metastasis.

  2010influential reference
• Macrophage plasticity and interaction with lymphocyte subsets: cancer as a paradigm

  2010cited by this paper
• Selective BRAFV600E inhibition enhances T-cell recognition of melanoma without affecting lymphocyte function.

  2010cited by this paper
• CD4(+) T cells contribute to the remodeling of the microenvironment required for sustained tumor regression upon oncogene inactivation.

  2010cited by this paper
• Dual targeting of EGFR can overcome a major drug resistance mutation in mouse models of EGFR mutant lung cancer.

  2009cited by this paper
• Inducible cutaneous inflammation reveals a protumorigenic role for keratinocyte CXCR2 in skin carcinogenesis.

  2009cited by this paper
• Conditional mouse lung cancer models using adenoviral or lentiviral delivery of Cre recombinase

  2009cited by this paper
• From phagocyte diversity and activation to probiotics: Back to Metchnikoff

  2008cited by this paper
• Oncogenic Ras-induced secretion of IL6 is required for tumorigenesis.

  2007cited by this paper
• Analysis of Gene Expression Data Using BRB-Array Tools

  2007cited by this paper
• Monitoring EGFR-mutant lung cancers by means of the blood.

  2006cited by this paper
• Clinical and biological features associated with epidermal growth factor receptor gene mutations in lung cancers.

  2006cited by this paper
• K-ras activation generates an inflammatory response in lung tumors

  2006cited by this paper
• Lung adenocarcinomas induced in mice by mutant EGF receptors found in human lung cancers respond to a tyrosine kinase inhibitor or to down-regulation of the receptors.

  2006cited by this paper
• A growth-related oncogene/CXC chemokine receptor 2 autocrine loop contributes to cellular proliferation in esophageal cancer.

  2006cited by this paper
• The impact of human EGFR kinase domain mutations on lung tumorigenesis and in vivo sensitivity to EGFR-targeted therapies.

  2006cited by this paper
• A distinctive alveolar macrophage activation state induced by cigarette smoking.

  2005cited by this paper
• Anti-inflammatory properties of the novel antitumor agent yondelis (trabectedin): inhibition of macrophage differentiation and cytokine production.

  2005cited by this paper
• Macrophage and mast-cell invasion of tumor cell islets confers a marked survival advantage in non-small-cell lung cancer.

  2005cited by this paper
• Epidermal growth factor receptor mutations and gene amplification in non-small-cell lung cancer: molecular analysis of the IDEAL/INTACT gefitinib trials.

  2005cited by this paper
• Ras-induced interleukin-8 expression plays a critical role in tumor growth and angiogenesis.

  2004cited by this paper
• The chemokine system in diverse forms of macrophage activation and polarization.

  2004cited by this paper
• Exploration, normalization, and summaries of high density oligonucleotide array probe level data.

  2003cited by this paper
• The role of tumour‐associated macrophages in tumour progression: implications for new anticancer therapies

  2002cited by this paper
• Proto-oncogene PML controls genes devoted to MHC class I antigen presentation

  1998cited by this paper
• SUPPLEMENTARY NOTE

  1879cited by this paper
• Cancer,Facts and Figures about.

  year unknowncited by this paper

• Glycolytic reprogramming of resident alveolar macrophages contributes to reduced SOCS3 secretion in non-small cell lung cancer

  2026cites this paper
• Immunotherapy after EGFR-TKI treatment in advanced non-small cell lung cancer: Current status and future perspectives (Review)

  2026influential citation
• Deficiency of lysosomal TMEM175 in myeloid macrophages exerts anti-tumor immunity via inflammasome and cross-presentation pathway.

  2026cites this paper
• Colony-stimulating factor-1 receptor inhibitor augments osimertinib-induced anti-tumor immunity via suppression of macrophages in lung cancer harboring EGFR mutation.

  2025cites this paper
• Overexpression of SERPINA3 inhibits castration-resistant prostate cancer progression by enhancing M1 macrophage recruitment via CXCL2 upregulation

  2025cites this paper
• Murine models of lung adenocarcinoma: Valuable tools for preclinical investigation.

  2025cites this paper
• Alveolar macrophages maintain tissue localization and gain enhanced anti-tumor activity in Lewis lung carcinoma-reprogrammed lung microenvironment

  2025cites this paper
• ZEB2 upregulation modulates the polarization of TAMs toward the immunosuppressive state in EGFR-TKI-resistant NSCLC

  2025cites this paper
• EGFR-driven lung adenocarcinomas coopt alveolar macrophage metabolism and function to support EGFR signaling and growth.

  2024cites this paper
• Immunological features of EGFR-mutant non-small cell lung cancer and clinical practice: a narrative review

  2024cites this paper
• Targeting tumor-associated macrophages to reverse antitumor drug resistance

  2024cites this paper
• Harnessing Natural Killer Cells for Lung Cancer Therapy.

  2023cites this paper
• Diagnosis of primary lung cancer and benign pulmonary nodules: a comparison of the breath test and 18F-FDG PET-CT

  2023cites this paper
• Changes of tumor microenvironment in non-small cell lung cancer after TKI treatments

  2023cites this paper
• Targeting tumor-associated macrophages with STING agonism improves the antitumor efficacy of osimertinib in a mouse model of EGFR-mutant lung cancer

  2023cites this paper
• Breaking the Invisible Barriers: Unleashing the Full Potential of Immune Checkpoint Inhibitors in Oncogene-Driven Lung Adenocarcinoma

  2023cites this paper
• EGFR+ lung adenocarcinomas coopt alveolar macrophage metabolism and function to support EGFR signaling and growth

  2023influential citation
• Using artificial intelligence to identify tumor microenvironment heterogeneity in non-small cell lung cancers.

  2023cites this paper
• Biosensor Detection of COVID-19 in Lung Cancer: Hedgehog and Mucin Signaling Insights.

  2023cites this paper
• Tumor-associated macrophages mediate resistance of EGFR-TKIs in non-small cell lung cancer: mechanisms and prospects

  2023cites this paper
• Single-cell RNA sequencing reveals the cellular and molecular changes that contribute to the progression of lung adenocarcinoma

  2022cites this paper
• Changes in the concentration of EGFR-mutated plasma DNA in the first hours of targeted therapy allow the prediction of tumor response in patients with EGFR-driven lung cancer

  2022cites this paper
• Research Progress in Immunotherapy of NSCLC With EGFR-Sensitive Mutations

  2022cites this paper
• Natural compounds: A new perspective on targeting polarization and infiltration of tumor-associated macrophages in lung cancer.

  2022cites this paper
• EGFR-Mutated Non-Small Cell Lung Cancer and Resistance to Immunotherapy: Role of the Tumor Microenvironment

  2022cites this paper
• Therapeutic targeting of macrophage plasticity remodels the tumor-immune microenvironment.

  2022cites this paper
• Co-dependencies in the tumor immune microenvironment

  2022cites this paper
• Chronic exposure to carbon black ultrafine particles reprograms macrophage metabolism and accelerates lung cancer

  2022cites this paper
• Macrophage renewal modes affect acquired resistance to gefitinib in EGFR‑mutant lung cancer PC‑9 cells.

  2022cites this paper
• Immune Subtyping in Latent Tuberculosis

  2021cites this paper
• Macrophages-based immune-related risk score model for relapse prediction in stage I–III non-small cell lung cancer assessed by multiplex immunofluorescence

  2021cites this paper
• Mad2 Induced Aneuploidy Contributes to Eml4-Alk Driven Lung Cancer by Generating an Immunosuppressive Environment

  2021cites this paper
• Tumor immune microenvironment in epidermal growth factor receptor-mutated non-small cell lung cancer before and after epidermal growth factor receptor tyrosine kinase inhibitor treatment: a narrative review

  2021cites this paper
• Overcoming microenvironmental resistance to PD-1 blockade in genetically engineered lung cancer models

  2021cites this paper
• Systemic Inflammatory Markers of Survival in Epidermal Growth Factor-Mutated Non-Small-Cell Lung Cancer: Single-Institution Analysis, Systematic Review, and Meta-analysis.

  2021cites this paper
• Targeting alveolar macrophages shows better treatment response than deletion of interstitial macrophages in EGFR mutant lung adenocarcinoma

  2020cites this paper
• Insulin-like growth factor-1 receptor induces immunosuppression in lung cancer by upregulating B7-H4 expression through the MEK/ERK signaling pathway.

  2020cites this paper
• Effect of COVID-19 on Lungs: Focusing on Prospective Malignant Phenotypes

  2020influential citation
• Overexpression of B7-H4 promotes renal cell carcinoma progression by recruiting tumor-associated neutrophils via upregulation of CXCL8

  2020cites this paper
• EGFR‐targeted therapy alters the tumor microenvironment in EGFR‐driven lung tumors: Implications for combination therapies

  2019cites this paper
• Tumor associated macrophages support the growth of FGF9-induced lung adenocarcinoma by multiple mechanisms.

  2018cites this paper
• Tumor regression mediated by oncogene withdrawal or erlotinib stimulates infiltration of inflammatory immune cells in EGFR mutant lung tumors

  2018cites this paper
• The lung microenvironment: an important regulator of tumour growth and metastasis

  2018cites this paper
• Studying the immune landscape in lung cancer models: choosing the right experimental tools.

  2018influential citation
• Tumor-derived thymic stromal lymphopoietin enhances lung metastasis through an alveolar macrophage-dependent mechanism

  2017cites this paper
• The Dr. Jekyll and Mr. Hyde complexity of the macrophage response in disease

  2017cites this paper
• M6a Regulator-Mediated RNA Methylation modi�cation Patterns Correlated With Prognosis Value and Immune Response in Adenocarcinoma of lung

  year unknowncites this paper